Original from: FinSMEs
Ginkgo Bioworks (NYSE: DNA), a Boston, MA-based company which is building a platform for cell programming and biosecurity, announced the acquisition of Proof Diagnostics, a life sciences tools, diagnostics and computational discovery company.
The amount of the deal was not disclosed.
With the acquisition, Ginkgo Bioworks will expand its offerings.
Proof was founded by Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs. Omar Abudayyeh and Jonathan Gootenberg of the McGovern Institute for Brain Research at MIT, and Sid Shenai to develop a low cost, rapid, easy-to-use, and sensitive diagnostic system ¨C for SARS-CoV-2, Flu A/B, RSV and other diseases, including oncology ¨C using CRISPR-based and other technologies.
